The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ACELYRIN INC | COM | 00445A100 | 28,739,426 | 3,852,470 | SH | SOLE | 3,852,470 | 0 | 0 | ||
ALX ONCOLOGY HLDGS INC | COM | 00166B105 | 144,431,883 | 9,699,925 | SH | SOLE | 9,699,925 | 0 | 0 | ||
ELEVATION ONCOLOGY INC | COM | 28623U101 | 1,564,955 | 2,914,255 | SH | SOLE | 2,914,255 | 0 | 0 | ||
HARMONY BIOSCIENCES HLDGS IN | COM | 413197104 | 33,443,291 | 1,035,396 | SH | SOLE | 1,035,396 | 0 | 0 | ||
IMPEL PHARMACEUTICALS INC | COM | 45258K109 | 340,834 | 2,759,791 | SH | SOLE | 2,759,791 | 0 | 0 | ||
PHARVARIS N V | COM | N69605108 | 137,992,087 | 4,919,504 | SH | SOLE | 4,919,504 | 0 | 0 | ||
RAYZEBIO INC | COM | 75525N107 | 320,682,932 | 5,158,162 | SH | SOLE | 5,158,162 | 0 | 0 |